medwireNews: A phase 2 trial update for hypoxia-inducible factor-2α inhibitor MK-6482 in patients with treatment-naïve renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease has been presented at the ESMO Virtual Congress 2020.
Initial positive findings reported at virtual 2020 ASCO Annual Meeting for the small-molecule agent were updated by Ramaprasad Srinivasan (National Cancer Institute, Bethesda, Maryland, USA) after a median follow-up of 68.7 weeks.
The objective response rate (ORR) was 36.1% for the 61 patients given MK-6482 at a dose of 120 mg/day, with a further 62.3% of patients achieving stable disease. Median duration of response remains unreached and median 1-year progression-free survival is 98.3%, with 91.8% of patients continuing treatment, the investigator said.
Improvements were also seen for non-RCC lesions associated with VHL disease. Of 61 patients with pancreatic lesions, 63.9% achieved at least a partial response, as did 30.2% of 43 patients with central nervous system hemangioblastoma, and an improvement was reported by 68.8% of the 16 patients with retinal lesions.
Srinivasan noted that anemia was the most common adverse event at any grade (90.2%) and grade 3 (6.6%) but that this “was an expected on-target side effect of this agent” and “amenable to medical management.”
He concluded: “MK-6482 has a favourable safety profile and has demonstrated durable efficacy in patients with VHL disease-associated renal cell carcinoma, as well as non-renal tumors.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group